Nonarteritic Anterior Ischemic Optic Neuropathy
Conditions
Keywords
NAION, ischemic optic neuropathy
Brief summary
This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION. All participants enrolled in Cohort A of the study will have a documented history of NAION for at least 12 months and at most, five years prior to enrollment. Participants enrolled in Cohort B of the study will have a documented history of NAION for at least 6 months and at most, three years prior to enrollment.
Detailed description
This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of SC administration of RPh201 in participants with previous NAION. Following a screening phase of 1-8 weeks, participants will attend a baseline visit in which they will undergo testing and visual function assessments. Participants then will be randomized to receive RPh201 or control. Cohort A After randomization, participants will begin a 26-week schedule consisting of twice-weekly treatment. Participants will return to the clinic for visits at Week 1, Week 4, Week 12 and Week 26 and Week 52 Cohort B After randomization, participants will begin a 12-week schedule consisting of four-times-per-week treatment. Participants will return to the clinic for visits at Week 4 and Week 12. Safety and efficacy parameters will be recorded throughout the duration of the study.
Interventions
DRUGRPh201 Cohort A
RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
OTHERPlacebo Cohort A
The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
DRUGRPh201 Cohort B
RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
OTHERPlacebo Cohort B
The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
Sponsors
Regenera Pharma Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
All clinic staff and participants will be masked to group assignments. Only the Data and Safety Monitoring Board (DSMB) and designated unmasked staff at the Coordinating Center will have access to the group assignments.
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(Cohort A): 1. The participant must be 50 years of age or older at the time of the NAION episode in the study eye. This means that the participant's age at enrollment must be greater than or equal to the sum of 50 plus the number of years since NAION (e.g., at least 52 years of age if the episode was two years prior). 2. The participant must understand the nature of the procedure and provide written informed consent prior to any study procedure. 3. The participant has a definitive clinical diagnosis of NAION in the study eye that developed at least 12 months before randomization. Specifically, the disc swelling must have been observed and documented (by examination, OCT or photograph) by an ophthalmologist or neuro-ophthalmologist who previously examined the participant at the time of the NAION episode in the study eye during the acute episode. 4. The participant's study eye must have disc pallor (global or segmental) present. 5. The participant's study eye must have stable visual acuity (see Sections 5.3.3 and 5.3.4). 6. Using the study eye, the participant must read at least 20 and at most 66 EVA letters with best-corrected vision, at each Screening visit. 7. The participant's study eye must have a HVF 24-2 SITA Standard visual field using spot size III with mean deviation -5 dB or worse and with a visual field defect compatible with NAION in the study eye (criteria in the MOP).
Exclusion criteria
(Cohort A): 1. The participant has received treatment for cancer within 12 months prior to enrollment (excluding localized basal cell carcinoma or localized squamous cell carcinoma) or had past diagnosis of cancer adjacent to the afferent visual pathway or had past diagnosis of metastatic cancer. 2. The participant had surgery, requiring general anesthesia with intubation, within 30 days prior to enrollment. 3. The participant is pregnant or a woman of child-bearing potential not using an acceptable method of contraception (per Section 4.1 of the protocol). 4. The participant is breast-feeding or plans to breast-feed. 5. The participant has had treatment with drugs that have potential neuroprotective or toxic effects on the optic nerve or retina (e.g., ethambutol, amiodarone, linezolid, hydroxychloroquine, fingolimod, brimonidine) within 6 months prior to enrollment. 6. The participant has participated in another interventional clinical trial within 60 days prior to enrollment, or previously participated in another clinical trial of RPh201 at any time. 7. The participant has been receiving or has received within three months prior to enrollment, corticosteroids (except topical steroids, steroid inhalers or intermittent injections into a joint or back), or immunosuppressive drugs. 8. The participant has a medical condition, social or psychological issue, or other condition which, in the judgment of the investigator, could be a safety concern or preclude the individual from completing the protocol. 9. The participant has a known allergy to cottonseed oil. 10. The participant is planning to move and not relocate near a study site and is unwilling to travel for appointments. 11. The participant cannot self-administer or arrange for administration of the IP. 12. The participant has one or more of the following abnormal test results at screening: * Erythrocyte Sedimentation Rate (ESR) above age/2 for men or \[age + 10\]/2 for women, as measured by Westergren method or equivalent. * Platelets \>400,000 mm3 * C-reactive protein (CRP) greater than two times the laboratory upper limit of normal. * Severe anemia (Hgb \< 10) 13. The participant has symptoms, signs, and/or diagnosis of giant cell arteritis at any time. 14. The participant has any other optic neuropathies (e.g., optic neuritis or glaucoma) in either or both eyes (other than self-limited optic neuropathies in the non-study eye, such as past traumatic optic neuropathy or past transient steroid-induced glaucoma due to localized steroid administration). 15. The participant has systemic inflammatory or infectious disease associated with optic neuropathy or ocular disease. 16. The participant has a history of uveitis in the study eye within the last 10 years. 17. The participant's study eye has an ocular condition that appears consistent with a reduction in visual acuity to \<20/25, diabetic retinopathy beyond mild non-proliferative diabetic retinopathy not involving the macula, or vision-threatening macula disease. 18. The participant has a visual field defect with homonymous non-altitudinal features or a defect that respects the vertical meridian. Inclusion Criteria (Cohort B): 1. The participant must be 50 years of age or older at the time of the NAION episode in the study eye. This means that the participant's age at enrollment must be greater than or equal to the sum of 50 plus the number of years since NAION (e.g., at least 52 years of age if the episode was two years prior). 2. The participant must understand the nature of the procedure and provide written informed consent prior to any study procedure. 3. The participant has a definitive clinical diagnosis of NAION in the study eye that developed at least 6 months and no more than 3 years before randomization. Specifically, the disc swelling must have been observed and documented (by examination, OCT or photograph) by an ophthalmologist or neuro-ophthalmologist who previously examined the participant at the time of the NAION episode in the study eye during the acute episode. 4. The participant's study eye must have disc pallor (global or segmental) present. 5. The participant's study eye must have stable visual acuity (see Sections 5.3.3 and 5.3.4). 6. Using the study eye, the participant must read at least 20 and at most 66 EVA letters with best-corrected vision, at each Screening visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change in number of best-corrected visual acuity (BCVA) letters from baseline to Week 26 (Cohort A) measured using electronic visual acuity (EVA). | Week 26 or Week 12 | Visual acuity |
| The change in number of best-corrected visual acuity (BCVA) letters from baseline to Week 12 (Cohort B) measured using electronic visual acuity (EVA). | Week 12 | Visual acuity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of study eyes improving from baseline in five or more locations of the Humphrey visual field (HVF) 24-2 full-threshold with the size V stimulus on the glaucoma change probability map (GCPM) at the 5% level by group. | Week 26 | Humphrey visual field (HVF) |
| The proportion of study eyes improving by a 15-letter score or more in BCVA from baseline to Week 26 using EVA (Cohort A). | Week 26 | Visual acuity |
| The proportion of study eyes improving by a 10-letter score or more in BCVA from baseline to Week 12 (Cohort B) using EVA. | Week 12 | Visual acuity |
| The proportion of study eyes improving by a 10-letter score or more in BCVA from baseline to Week 26 (Cohort A) using EVA. | Week 26 | Visual acuity |
| The proportion of study eyes improving by a 15-letter score or more in BCVA from baseline to Week 12 (Cohort B). | Week 12 | Visual acuity |
Other
| Measure | Time frame | Description |
|---|---|---|
| The proportion of study eyes improving by 7 dB or more in five or more locations measured with HVF 24-2 SITA using the size III stimulus. | Week 12 | Humphrey visual field (HVF) |
| The change in sensitivity on HVF-24-2 full-threshold with the size V stimulus. | Week 26 | Humphrey visual field (HVF) |
| The change in mean deviation measured with HVF 24-2 SITA using the size III stimulus. | Week 12 | Humphrey visual field (HVF) |
| The change in number of BCVA letters | Week 52 | Visual acuity |
| The proportion of study eyes improving by a 10-letter score or more in BCVA from baseline using EVA. | Week 52 | Visual acuity |
| The proportion of study eyes improving by a 15-letter score or more from baseline in BCVA by group. | Week 52 | Visual acuity |
| The mean change in sensitivity from baseline on HVF 24-2 full-threshold with the size V stimulus. | Week 52 | Humphrey visual field (HVF) |
| The proportion of study eyes improving in five or more locations from baseline of the HVF 24-2 full-threshold with the size V stimulus by GCPM at the 5% level by group. | Week 52 | Humphrey visual field (HVF) |
| The proportion of study eyes improving in mean deviation by 7 dB or more measured with HVF 24-2 SITA using the size III stimulus. | Week 12 | Humphrey visual field (HVF) |
Countries
United States
Outcome results
None listed